CEO at Johnson & Johnson vaccine plant company got 51% raise in 2020

Emergent BioSolutions, the manufacturer at the center of the Johnson & Johnson coronavirus vaccine bungle, gave its chief executive officer a 51 percent compensation bump in 2020 — bringing his total remuneration to a whopping $5.6 million.

On top of a lucrative $893,000 salary, CEO Robert Kramer received a $1.2 million bonus and $3.5 million in stock awards and options, according to the company’s filing with the Securities & Exchange Commission late Friday. Emergent’s response to the COVID-19 pandemic last year contributed Kramer’s juiced-up compensation package, the company said, citing the expansion of its contract manufacturing business.